VTV.vn - Pfizer Vietnam, in collaboration with Vietnam Cancer Association and Vietnam Cancer Immunotherapy Association, ...

The breast cancer treatment market is rapidly growing, driven by advances in technology, personalized therapies and early diagnosis efforts.

Health experts discuss advanced biologic therapies in breast cancer treatment at a recent symposium in Hà Nội.

RHHBY's Itovebi combo wins CHMP backing for PIK3CA-mutated breast cancer, showing strong survival benefits in phase III ...

Gilead Sciences, Inc. GILD announced positive top-line results from yet another late-stage study on breast cancer drug, ...

Gilead Sciences’ randomised, global Phase III ASCENT-03 trial of Trodelvy (sacituzumab govitecan-hziy) has met its primary ...

Pfizer has struck a massive $1.25 billion deal with China’s 3SBio to license a promising cancer drug, beefing up its oncology ...

After a blood test during her annual physical uncovered low hemoglobin levels, she underwent numerous tests and learned she had Stage 3 colorectal cancer. “They found a softball- and golf ball ...

Itovebi (inavolisib) has been dealt a boost after the drug demonstrated further positive overall survival (OS) data in a ...

The Itovebi, Ibrance, and fulvestrant combination demonstrated improved survival outcomes versus placebo in a Phase III trial.

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) said that an advisory panel of the European Medicines Agency (EMA), endorsed its Itovebi ...